NCT04640779
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +24 more
- Locations
-
- Mayo Clinic in Rochester Rochester, Minnesota, United States
Clinical trial condition
Refractory Histiocytic and Dendritic Cell Neoplasm
Explore clinical trials studying Refractory Histiocytic and Dendritic Cell Neoplasm. Study availability and eligibility vary by location and protocol.
3 public trials
0 recruiting studies
Refractory Histiocytic and Dendritic Cell Neoplasm trial results
Active, Not Recruiting
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
NCT03698994
- Conditions
- Advanced Malignant Solid Neoplasm, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ependymoma, +83 more
- Locations
-
- Children's Hospital of Alabama Birmingham, Alabama, United States
- Providence Alaska Medical Center Anchorage, Alaska, United States
- Banner Children's at Desert Mesa, Arizona, United States
- Banner University Medical Center - Tucson Tucson, Arizona, United States
Active, Not Recruiting
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
NCT04320888
- Conditions
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ependymoma, Female Urogenital Diseases, +85 more
- Locations
-
- Children's Hospital of Alabama Birmingham, Alabama, United States
- Providence Alaska Medical Center Anchorage, Alaska, United States
- Banner Children's at Desert Mesa, Arizona, United States
- Phoenix Childrens Hospital Phoenix, Arizona, United States